Nh?ng trò choi m?o hi?m

 

 If we are unable to raise the required capital, we may be forced to curtail our activities and, ultimately, cease operations  Nh?ng trò choi m?o hi?m  Our plans include an additional clinical study of istaroxime in early cardiogenic shock, an area that we have not studied previously. To gain marketing authorization for new indications such as early cardiogenic shock, we will need to engage with the US Food and Drug Administration (FDA) and successfully complete our clinical program. We may not reach agreement with the US Food and Drug Administration (FDA) or a foreign regulator on the extent of our clinical program, the design of any one or more of the clinical trials necessary for approval. We may suffer significant delays or setbacks in any stage of our clinical trials. and if our results are inconclusive or non-compelling or otherwise insufficient to support a strategic or financing transaction, we potentially could be forced to limit or cease all development activities, which would have a material adverse effect on our business.